PRESS RELEASE published on 09/08/2026 at 07:30, 1 month 29 days ago Informations privilégiées / Autres communiqués GenSight Biologics fait un point sur ses activités de fabrication, cliniques et financières, confirmant la date de publication des comptes semestriels 2026 Fabrication GenSight Biologics Thérapies Géniques Comptes Semestriels Actifs Cliniques
BRIEF published on 07/08/2026 at 19:16, 3 months 29 days ago GenSight Biologics presents its financial situation and therapeutic advances Treasury GenSight Biologics Phase III RECOVER Early Access GS010/LUMEVOQ®
BRIEF published on 07/08/2026 at 19:16, 3 months 29 days ago GenSight Biologics présente sa situation financière et ses avancées thérapeutiques Trésorerie GenSight Biologics Phase III RECOVER GS010/LUMEVOQ® Accès Précoce
BRIEF published on 07/08/2026 at 19:16, 3 months 29 days ago GenSight Biologics annonce sa situation de trésorerie et des mises à jour sur ses activités Essais Cliniques Actualités Commerciales Position De Trésorerie Programmes D'accès Anticipé Processus De Fabrication
BRIEF published on 07/08/2026 at 19:16, 3 months 29 days ago GenSight Biologics Announces Cash Position and Business Updates Cash Position Clinical Trials Business Updates Early Access Programs Manufacturing Process
PRESS RELEASE published on 07/08/2026 at 19:11, 3 months 29 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation de trésorerie au 30 juin 2026 et fait un point sur son activité. La trésorerie est de 1,7 million d'euros, encaissant 6,8 millions d'euros au titre de ses programmes d'accès précoce Trésorerie GenSight Biologics Thérapies Géniques Neuropathie Optique Programmes D'accès Précoce
PRESS RELEASE published on 07/08/2026 at 19:11, 3 months 29 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position updates as of June 30, 2026, along with business developments, including proceeds from early access programs and manufacturing process improvements Cash Position Business Updates GenSight Biologics Early Access Programs Manufacturing Process
BRIEF published on 04/28/2026 at 20:40, 6 months 8 days ago GenSight Biologics announces its 2026 Combined General Meeting Shareholders Gene Therapy General Assembly Preparatory Documents GenSight Biologics
BRIEF published on 04/28/2026 at 20:40, 6 months 8 days ago GenSight Biologics programme son assemblée générale annuelle pour mai 2026 Conformité Réglementaire Assemblée Générale Annuelle Thérapie Génique Relations Avec Les Investisseurs Informations Destinées Aux Actionnaires
BRIEF published on 04/28/2026 at 20:40, 6 months 8 days ago GenSight Biologics Schedules Annual General Meeting for May 2026 Annual General Meeting Regulatory Compliance Shareholder Information Investor Relations Gene Therapy
Published on 11/06/2026 at 22:15, 16 hours 40 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 1 day 1 hour ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 1 day 2 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 1 day 2 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/07/2026 at 13:35, 1 hour 20 minutes ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 18 hours 40 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 20:15, 18 hours 40 minutes ago L’Agence africaine des médicaments marque sa première année d’activité avec le lancement de nouvelles plateformes pour renforcer la réglementation et soutenir la fabrication
Published on 11/06/2026 at 19:15, 19 hours 40 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 19 hours 55 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 19:06, 19 hours 48 minutes ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 19 hours 51 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 19 hours 53 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 19 hours 55 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
